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ABSTRACT 
This thesis reports on using label-free optical sensors for multiplexed detection of 
autoantibodies for Type 1 Diabetes. An autoimmune disease that occurs when the body 
either does not produce enough or stops producing insulin, the hormone that controls 
blood-sugar levels. Autoantibodies working against islet antigens such as insulin, 
glutamic acid decarboxylase (GAD), and insulinoma associated protein-2 (IA-2) have 
been well-confirmed in Type 1 Diabetes (T1D) panels. While clinical diagnosis of T1D 
can be performed by detecting the level of autoantibodies in a blood sample, sensitive 
detections are especially crucial for predictive analysis and early screening of potential 
diabetes victims.  
The label-free optical sensor was made from Anodic Aluminum Oxide (AAO), a 
self-organized material formed by high-density arrays of uniform and parallel porous 
nanostructures, which has been widely utilized in biomedical sensing and bioanalysis 
area. We have demonstrated multiplexed detection of autoantibodies using label-free 
optical sensors that can readily detect as a small level as 0.1 U/ml of three autoantibodies 
in human serum. In addition, the specificity of the sensor has also been evaluated by 
detecting autoantibodies in a nonspecific antigen with results reflecting good specificity. 
Moreover, multiplexed detection of insulin, GAD, and IA-2 antibodies in serum using 




CHAPTER 1.    GENERAL INTRODUCTION 
1.1 Research Motivation 
Diabetes is a chronic disease that occurs either when the human pancreas does not 
produce enough insulin, or the body ineffectively uses the insulin it does produce. Insulin is a 
type of hormone that takes control of the blood-sugar levels within a reasonable range. 
Hyperglycemia or high blood sugar, a common side effect of diabetes, can trigger havoc on 
organs, especially blood vessels, kidneys, and the nerve system, elevating the risk of heart 
attack and stroke over time.    
There are two main kinds of diabetes, Type 1 and Type 2. Type 1 diabetes, also 
known as insulin-dependent or juvenile diabetes, is an autoimmune disease, characterized by 
deficiency in production of insulin, caused by the immune system attacking itself, with the 
body attacking the insulin-producing beta cell (islet cell). [1] Over time, the number of islet 
cells could be tremendously reduced until none remain in the body, so body cannot produce 
its own insulin, resulting in disuse of glucose in bloodstream, i.e., without insulin, the body 
cannot obtain energy from blood glucose. Type 1 Diabetes is neither preventable nor curable, 
is of uncertain cause, and requires lifelong treatment once developed, while Type 2 Diabetes 
is preventable and sometimes it can be reversed. The pathogenesis of Type 2 Diabetes is the 
body’s improper use of insulin and body resist the insulin [1], with free fatty acids promoting 
loss of insulin sensitivity in such a case.[2] The majority of people with diabetes have Type 2 
Diabetes, and the main reasons for T2D are obesity and lack of physical exercise.[3] 
According to World Health Organization (WHO) statistics, the number of people with 
diabetes has risen from 108 million in 1980 to 440 million in 2014, and around the world 
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rates of incidence of Type 1 Diabetes are rising; in the United States, approximately 1.25 
million American have Type 1 diabetes and by 2050, 5 million people are expected to be 
diagnosed with that disease. While it is usually diagnosed in children, youth, but it can 
develop at any age. Between 2011 and 2012, approximately 17,900 children and juvenile 
under the age of 20 have been diagnosed with Type 1 Diabetes, and the likelihood. Of being 
diagnosed with T1D under the age of 20 is still increasing. By 2050, 600,000 people under 
the age of 20 are expected to be diagnosed as having Type 1 Diabetes. [4] [5]   
TrailNet, an NIH-funded international network of research centers, claimed that 
diagnosing Type 1 Diabetes as early as possible before beta cells (islet cells) completely 
disappear is important in reducing the risk of T1D. [6] For most people with T1D, the disease 
seems to take place suddenly, often accompanied by severe symptoms. Research studies state 
that Type 1 Diabetes can be divided into three different stages. Stage 1 occurs at the 
beginning of the T1D, with individuals testing positive for two or more autoantibodies, 
indicating the immune system has begun attacking beta cells, although at this stage, the 
blood-sugar level within a normal range. Advancing to stage 2, in which a victim tests 
positive for two or more diabetes-related autoantibodies, blood-sugar levels become 
abnormal and the beta cell damage continues. At stage 3, T1D can be clinically diagnosed by 
recognition of a great loss of beta cells, and other common symptoms of T1D. Earlier 
diagnosis is therefore extremely important to either reduce the risk of having T1D or trigger 
its satisfactory management by intervening with loss of the beta cell during the early T1D 
stage. However, because of testing expense, people tend not participate in early screening if 
they have no symptoms of Type 1 Diabetes. 
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Because of the increased number of people under age 20 who are suffering from the 
torment of Type 1 Diabetes, I have introduced a method for rapid detection of the three main 
autoantibodies for Type 1 Diabetes using a label-free optical sensor based on Anodic 
Aluminum Oxide (AAO) substrate suitable for bioanalysis.  
In this thesis, some of current state-of-the-art with detection of autoantibodies will be 
discussed, along with details of experiment procedures, fabrication process, and results. 
 
1.2 Thesis Organization 
The following chapters focus mainly on experimental details, including the sensor’s 
operating principle, experiment process, experimental results and fabrication flow of sensor. 
Chapter 2 discusses the operational principles of the Anodic Aluminum Oxide (AAO)-based 
thin film sensor, experimental procedures, and discussion of study’s results, that describe 
sensor sensitivity to change in concentration of autoantibodies. Furthermore, it will also 
describe further experiments related to specificity test, in which detection of the 
autoantibodies related to nonspecific antigen was used to evaluate the sensor’s specificity 
with good results. 
Chapter 3 will demonstrate the details of label-free optical sensor integrated on chip 
fabrication flow and will describe the procedures whereby a microfluidic interface and AAO 
based optical sensor integrated onto a chip. Additional applications of this sensor will also be 
discussed. Appendix A describes the mechanism of anodic aluminum oxide formation. [7] 
Appendix B provides the protocol of the surface functionalization process and describes the 
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materials used in the experiment. Appendix C provides detailed information regarding the 
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CHAPTER 2.    DETECTION OF AUTOANTIBODIES FOR TYPE 1 DIABETES 
USING LABEL-FREE OPTICAL SENSOR 
Abstract  
Anodic Aluminum Oxide (AAO) was discovered almost a century ago and has been 
widely utilized. It has a honeycomb-like nanostructure characterized by arrays of uniform and 
parallel porous nanostructures. AAO has been considered as a promising nanomaterial for 
developing biosensing systems with remarkable performance, and recent studies have 
demonstrated use of AAO with other techniques, yielding numerous state-of-the-art sensors 
for use in bioanalysis and other applications. Beta cell (islet cell) autoantibodies such as 
insulin, glutamic decarboxylase (GAD), and insulinoma associated protein-2 (IA-2) are 
strongly related to the development of Type 1 Diabetes, and this chapter indicates the 
sensitive detection of concentration changes in these three autoantibodies on a surface 
functionalized Anodic Aluminum Oxide surface. 
  
2.1 Introduction  
Diabetes is a condition in which a high concentration of sugar or glucose exists in the 
bloodstream because either the body lacks insulin or doesn’t use insulin properly by not 
converting the sugar to energy. While the majority of diabetes cases occur because the body 
use insulin inappropriately, about 5% to 10% diabetes caused by lack of insulin, a condition 
called Type 1 Diabetes. [1]  
Although such deficiencies accounts for only a minority of diabetes cases, it 
maintains a severe chronic disease, usually developing at an earlier age than Type 2 Diabetes, 
and there is presently a significant trend toward its occurrence at decreasing age.  
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Type 1 Diabetes is a disease in which pancreatic islet cell destruction results in loss of 
insulin with the immune system attacking islet cells for unknown reason leading to the body’s 
inability to produce insulin. Detection of autoantibody levels of Type 1 Diabetes, including 
insulin, GAD, and IA-2 has been of great interest in exploring the diabetes’ pathogenesis. 
Approximately 66% of patients have tested positive with respect to autoantibody attacks 
insulin [2], while those against GAD are found in 80% of Type 1 Diabetes patients,[2] 16% of 
whom are under age of 25. [3] In addition, the presence of antibodies against IA-2 ranges from 
54% to 75%. [4] And, more importantly, children have a higher chance to develop Type 1 
Diabetes, with the peak age of diagnosis in the United State being about 14 years old. [5] 
Therefore, earlier diagnosis and predictive screening are particularly urgent in managing 
Type 1 Diabetes at an early stage for the new generation. Sensitive detection of 
autoantibodies against beta cell is especially essential for providing T1D predictive value.  
Currently, standard detection methods for diabetes autoantibodies use enzyme-link 
immunosorbent assay (ELISAs) [6] and radioimmunoassay (RIAs) [7]. ELISA is the most 
commonly used in clinical settings to provide accurate detection and quantification of bio-
agents. It is a reliable, sensitive method that requires a strict environment for proper detection 
to encounter the ELISA. However, ELISA does have obvious shortcomings; it is a labor-
intensive, complicated procedure, requires a large volume of sample, and is unable to realize 
the multiplexed detection. Besides, RIA, that can produce high-specific and high-sensitive 
results, also has some limitations; it can produce hazard radiation for the user, it’s time-
consuming, and it is restricted to use of radioactive material. Many approaches have been 
proposed to seek improved methods for autoantibodies detection, for instance, near-infrared 
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fluorescence-enhanced detection using a plasmonic gold chip [8], and multiplexed detection 
using microfluidic droplet array. [9] But there continues to be great need for a simple method 
of quantitative detection of all three antibodies in a single volume.   
 For this purpose, we have demonstrated a new method for rapid detection of 
autoantibodies against insulin, GAD and IA-2 using AAO based optical sensor. The label-
free optical sensor is a nanopore-structure-based substrate with a microfluidic interface 
device. The nanopore structure of such a substrate can utilized Anodic Aluminum Oxide 
(AAO) to facilitate autoantibody bio-detection. AAO has been discovered and widely used 
since the early 20th century, is a honeycomb-like structure characterized by arrays of uniform 
and parallel porous nanostructures, as shown in Fig 2.1(a), with the nanopore diameter size 
typically ranging from 20nm to 150 nm. A scanning electron microscope (SEM) image of the 
AAO surface is shown in Fig 2.1(b), and detailed formation mechanism of AAO are given in 
Appendix A. Because of its incredible performance, there is a great of interest in AAO as a 
promising nanomaterial for developing bio-detection. Recent studies have demonstrated that 
AAO can be used in other applications, such as detection of cancer biomarker and 
Alzheimer’s biomarkers [10] [11][14], pressure sensing [12], drug release and loading [13], 
detection of theophylline [15], detection of Alzheimer's disease [16] and nanostructured optical 
biosensor [17]. These applications have effectively used AAO along with other techniques to 





Fig 2. 1 (a) structure of the Anodic Aluminum Oxide, arrays of uniform and parallel 
nanopores. (b) SEM image of AAO showing the nanopores of the sensor  
 
2.2 Principle of Optical Sensor  
The label-free optical sensor uses the nanopore thin film AAO as a platform for 
facilitating antibody detection. Uniform and parallel nanopores of diameter of typically 
varying between 20 nm to 150 nm are distributed over the AAO thin film. Each nanopore 
formed as a cavity can be treated as a nanostructured Fabry-Perot interferometer (μFPI) that 
can offer advantages, such as increasing sensing surface area, extending penetration depth of 
incident light, and signal magnification. The operational principle is shown in Fig 2.2. When 
the optical fiber emits a signal on the surface on which there are autoantibodies bound to 
antigens, the optical signal (fringes) reflected from the sensor will be shifted due to the 
change in the effective optical thickness at the sensor surface, and this optical shift can be 




Fig 2. 2 Operational principle of sensor: when antigen (Ag) is bound to antibody (Ab), the 
fringes of the reflected optical signal shift 
 
2.3 Experimental Procedures 
The step-by-step surface functionalization procedure of the sensor is illustrated in Fig 
2.3. Three different antigens (insulin, GAD, IA-2) are functionalized on the sensor and 
thereby become capable of detection. More precisely, an AAO slide is prepared by coating it 
with a thin gold layer using the sputtering apparatus, followed by immereion of the Au-
coated AAO sample into a HSC10COOH/HSC8OH solution, and after incubating overnight at 
4℃, the AAO sample is washed with ethanol and deionized (DI) water respectively. After the 
surface has dried, 200 μL EDC/NHS is applied on the AAO surface and incubating at room 
temperature for two hours. The sensor surface is then washed with phosphate buffered saline 
(PBS) and DI water, and after the residual is removed, diabetes antigens are separately 
applied on the sensor surface and incubated overnight at 4℃. The antigens are then removed 
by rinsing several times with PBS and DI water, to ensure that no antigens residually remain 
on the surface, followed by dipping 200 μL EA solution on the surface at room temperature 
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to block non-occupied site activate by the EDC/NHS solution. After two hours, the AAO 
surface is rinsed multiple times with PBS and DI water to dispel any leftover EA solution, 
after which the optical signal (fringes) is recorded. At this point, the surface functionalization 
procedure has been completely carried out, and the AAO surface is ready to be used in the 
experiment.  
This experiment consists of two parts, incubation-time tests, and standard tests. The 
incubation time test is to determine how long it takes for the optical signal shift to become 
stable, while the standard test is to detect whether or not autoantibodies exist on the surface. 
During the incubation time test, the antigens functionalized AAO sample is immersed in 
solution containing corresponding antibodies at the highest sample concentration (50 U/ml 
for insulin antibodies, 50 U/ml, and 100U/ml). Note that the biomarkers of antibody 
concentrations are provided by the vendor, expressed in the international unit of U/ml. The 
sensor is shaken on a Shaker for a certain time, followed by cleaning step that includes, 
repeatedly rinsing the sensor with PBS and DI water, then recording the optical signal. These 
process, immersing sensor into solution, shaking it, cleaning it, and recording fringes at the 
specific accumulated time, are then repeated at selected times of 5 mins, 10 mins, 15 mins, 20 
mins, 30 mins, 45 mins, 60 mins, and 90 mins. The standard test includes, dipping into a 
different concentration of biomarker solution with a specific antibody on the antigen 
functionalized sensor, shaking for 45 mins (the result of the incubation time test), rinsing it 
with PBS and DI water, and recording the fringes. The concentrations of the antibodies 
hostile to insulin diluted in the buffer solution are 0 (sample buffer), 0.1 U/ml, 0.1U/ml, 0.4 
U/ml, 1.6U/ml, 6.3 U/ml, 12.5 U/ml, 50 U/ml, and the insulin-hostile antibodies diluted in 
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human serum at the same concentrations. The concentrations of antibody hostile to GAD 
diluted in human serum are 0 (human serum), 0.1 U/ml, 0.5 U/ml, 1 U/ml, 5 U/ml, 10 U/ml, 
and 50 U/ml, while the concentrations of antibody against IA-2 diluted in human serum are 0 
(human serum), 0.1 U/ml, 1 U/ml, 5 U/ml, 10 U/ml, 50 U/ml and 100 U/ml. 
Furthermore, specificity tests were implemented to evaluate the sensors specificity. 
The sensor was functionalized with antigens then evaluated with other types of antibodies, 
incubating GAD and IA-2 antibodies on the insulin antigen-functionalized sensor 
respectively, incubating insulin and GAD antibodies on the IA-2 antigen-functionalized 
sensor respectively, and incubating insulin and IA-2 antibodies on the GAD antigen-
functionalized sensor respectively using the standard processes. A total of 6 sets of tests will 
be performed. The same antibody concentrations used in standard test were used to 
implement the specificity test. A small fringe shift can be observed, possibly caused by non-




Fig 2. 3 Demonstration of the step by step surface functionalization process 
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2.4 Results and Discussion  
Typically, optical signals from sensor before and after applying the biomarker 
solution with antibodies will cause a signal shift, as shown in Fig 2.4, and the optical shift 
occurs between two different states of the sensor, at different incubation times, and with 
different antibody concentrations. In the incubation time test, read the shift between two 
time-nodes for each sample, until the signal remains unchanged, and calculate the average of 
each test for three autoantibodies. The incubation time test shows that, all three antibodies 
need approximately 30 to 45 minutes of incubation time to become saturated. The incubation-
time results are shown in Fig 2.5. 
 
Fig 2. 4 (a) Typical measured optical signal for GAD Ab at 0, 15 mins and 30 mins 
incubation time, fringes shift as the incubation time increased until saturated. (b) 
Measurement of insulin Ab with different concentration, 0, 0.4 U/ml, and 12.5 U/ml, the 







Fig 2. 5 (a) Insulin Ab saturation time around 30 to 45 mins (b) GAD Ab saturation time 
around 30 to 45 mins (c) IA-2 Ab saturation time around 30 to 45 mins 
 
For the incubation time test, since the saturation time for antibody hostile to insulin, 
GAD, and IA-2 ranges from 30 mins to 45 mins, in the following standard test, the sample 
was incubated (shake) for 45 mins, allowing enough time to let antibodies bind with antigens. 
Currently, as little as 0.1 U/ml of three autoantibodies can be readily detected in both buffer 
solution and serum, while up to 50 U/ml of insulin Ab and GAD Ab and up to 100 U/ml of 
IA-2 Ab can be detected. As the antibody concentrations increased, the optical signal would 





     
 
 Fig 2. 6 (a) Standard test of Insulin antibody as concentration from 0.01 U/ml to 50 U/ml in 
both serum and buffer. (b) Standard test of GAD antibody from 0.01 U/ml to 50 U/ml only in 
serum. (c) Standard test of IA-2 antibody from 0.01 U/ml to 100 U/ml only in serum. Note 
that concentrations of the anti-insulin in buffer are known provide by vendor (adi Inc), as 
well as the concentration of antibodies against GAD, IA-2 in serum are known provided by 
Kronus.  
Fig 2.6, the calibration curves with error bars indicate, optical signals occur when the 
concentration of antibodies increased, with a total of ~6 nm fringe shifts occurring in the 
insulin Ab test in the buffer along with a ~8.4 nm total shift in serum due to non-specific 
bindings in serum. Moreover, a total of ~ 8.2 nm and a total of ~9 nm fringes shift occurred 





range. For the anti-insulin sample, the lower detection limit is around 0.1 U/ml, and the 
detection limit of GAD antibody is also around 0.1 U/ml while the detection limit of anti-
GAD ELISA is 0.2 U/ml [19]. The lower anti IA-2 ELISA (IgG) was found to be 0.7 U/ml [19], 
while in our test, IA-2 antibodies’ detection limit is closed to 0.2 U/ml, more sensitive than 
available ELISA kit.    
Based on standards provided by the vendors (adi Inc and Kronus), the normal range of 
insulin should be less than 5 U/ml, border-line is between 5 U/ml and 10 U/ml, and diabetes 
can be diagnosed if insulin concentration is larger than 10 U/ml. For the GAD and IA-2 
antibodies, 5 U/ml is the threshold level, and once the concentration exceeds that value, 
diabetes can be confirmed.[20][21] Our optical sensor could easily detect the antibodies hostile 
to insulin, GAD, and IA-2 above the 5 U/ml level. To observe fringe shift in the samples, we 
could easily distinguish whether or not antibodies had bound with antigens. Overall, our 
sensor could successfully detect the autoantibodies against insulin, GAD, and IA-2 in the 
sample.  
Results of the specificity test are indicated in Fig 2.7. Antibodies would theoretically 
not bind with the non-specific antigen e.g.; insulin antibodies would bind with neither GAD 
antigens nor IA-2 antigens. After incubating antibodies on non-specific antigens for a certain 
time, antibodies can be washed away and ideally cause no fringe shift. Although in reality, 
the fringes will exhibit a certain amount of shift in such case, possibly generated by unknown 
elements presence in the serum that could, causes some non-specific binding, producing 





Fig 2. 7 (a) Specificity test of insulin antigens functionalized with three antibodies. (b) 
Specificity test of GAD antigen functionalized with three antibodies (c) Specificity test of IA-
2 antigen functionalized with three antibodies.  
 
As shown in Fig 2.7 (a), insulin antigen-functionalized sensor indicated that insulin 
antibodies bind with insulin antigens to produce 6 nm fringe shift in buffer and 8.4 nm fringe 
shift in serum, while there was only an approximately 2.1 nm shift for GAD Ab and less than 
a 2 nm shift for IA-2 Ab in this case. Fig 2.7 (b) shows a shift of less than 2 nm for both IA-2 





Ab. An approximate 3 nm shift for GAD Ab and 2 nm shift for insulin Ab emerged on the 
IA-2 Ag functionalized sensor, as shown in Fig 2.7 (c). 
Fringe shifts occurring in the specificity test, were much smaller than those in the 
standard test, as low as 0.5 U/ml of each autoantibodies can be distinguished from a mixed- 
antibodies sample from Fig 2.7, reflecting good specificity of this label-free optical sensor.  
Overall, the label-free sensor can successfully detect the autoantibodies against 
insulin, GAD, and IA-2, through observation of optical-signals shifts related to different 
antibody concentrations. While the non-specific binding caused by the unknown chemical 
composition in the antibody solvent (buffer or serum) will lead to a small amount of fringe 
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CHAPTER 3.    FABRICATION OF LABEL-FREE OPTICAL SENSOR WITH 
MICROFLUIDICS INTERFACE 
Abstract 
Microfluidics is extensively used in many multidisciplinary fields, like engineering, 
physics, chemistry, biotechnology and nanotechnology that use such devices to apply fluid 
flow to channel in a small dimension, usually less than 1 millimeter. Microfluidics has a 
number of useful advantages, including reduce reagent consumption, applicable to well-
controlled particle manipulation, and multiplexing screening. A microfluidic interface with 
the label-free optical sensor of this study can achieve multiplexed detection of autoantibodies 
against Type 1 Diabetes. There is a great need for quantitative detection of all three 
antibodies within a single volume, and the detailed fabrication process of the microfluidic 
surface for this purpose and the sensor’s micropattern process will be discussed in this 
chapter.  
 
3.1 Introduction  
 Manipulation of fluidics in channels at micro-scale or less, called microfluidics, has 
arisen as a unique field promising to influence multidiscipline from engineering, chemical, 
physics, and nanotechnology. The roots of microfluidics originated from three main different 
fields, microanalysis, biodefense, and microelectronics. It was first applied in 1970s [1] as a 
tool in microbiology by supporting operation of a small volume of sample and reagent in 
analysis to achieve a miniaturized gas chromatography on a silicon wafer. Still, another 
motivation for microfluidics resulted from chemical and biological weapon threats posed by 
the hostile parties, where microfluidics systems were designed in 1990s [2] to serve as 
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detectors for chemical biological threats, commissioned for fast and in-situ detection. 
Another contribution came from microelectronics in photolithography and related 
technologies used to form microfluidics devices using silicon or glass as raw materials. 
Although silicon was soon after replaced by polymer because of its low cost, high 
biocompatible, and transparency to UV light, a polymer is an elastomer, a more flexible 
material than rigid material silicon, with the important property of gas permeability, 
necessary for bio-detecting living cells in a microfluidic channel.  
Over the years, materials such as silicon, glass, and polymers have been used to 
fabricate microfluidic devices, although admittedly there are no perfect materials; as all have 
both merits and defects when utilized in microfluidics. While silicon was one of the first 
materials used in microfluidics because of its good thermal conductivity and surface stability, 
the drawback of silicon is obvious; it is opaque to visible or UV light, so it cannot be used for 
high-resolution optical detection. Polymers are widely used in microfluidics fabrication due 
to advantages like, biocompatibility. In contrast, they might absorb small hydrophobic 
molecules. But, their future is still bright.     
Most microfluidic systems have been implemented in polymer- polydimethylsiloxane 
(PDMS), a silicon-based organic polymer whose properties are somewhat different from 
silicon or glass. There are many reasons for PDMS becoming a popular material for 
fabricating microfluidic devices. It is transparent, and compatible the optical detection from 
240 nm to 1100 nm [4]. It has good deformability that can be used in valve application through 
channel deformation. It is also permeable to gases, and biocompatible, important properties in 
experiments involving living cells, or supplying gas supplying for cell cultures. Additionally, 
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PDMS is cost-effective, cheaper than silicon or glass. Hence, we employ PDMS as material 
to fabricate the microfluidics interface for the label-free optical sensor. The motivations for 
using microfluidics are that they can be used to greatly reduce the sample usage and 
multiplexed detection of autoantibodies using in a single chip, with the PDMS an appropriate 
material for realizing bio-detection.  
Soft lithography is a common technique used to fabricate PDMS structures. This 
process requires a mold to depicts the hollow space for the microfluidics channel. PDMS is a 
proportional mixture of silicon hydride groups and vinyl groups that can be poured on the top 
of a mold. Then Peeled off the PDMS from the mold after 2 hours curing at 75°C. The 
structure is ultimately transferred from the mold to a PDMS replica whose channel has no 
bottom. To form a closed channel, Plasma Bonding can be used to seal the PDMS to a 
surface, such as glass or silicon. As a result, a general microfluidic system is formed.  
A micropatterned AAO is important for integrating the label-free optical sensor with 
the microfluidics structure. The micropattern process has been successfully accomplished on 
the glass substrate using an anodization (one-step or two-step) process along with a lift-off 
process [3]. The properties of the micropattern AAO were evaluated to verify that its optical 
properties remain unchanged. Therefore, suggesting that the down-sized optical sensor stored 




3.2 Materials and Fabrication process  
1. Materials and chemicals 
Silicon wafer is purchased from Wafer World, Inc. Negative photoresist SU-8 2075 
and SU-8 developer are purchased from MicroChem, Inc. The positive photoresist AZ 5214-
E IR and AZ 300 MIF developer are purchased from EMD Performance Materials Corp. 
PDMS is 184 silicone elastomers purchased from SYLGARD™. And Aluminum etchant 
Type A is purchased from TRANSENE, Inc. AAO etchant is a mixture of phosphoric acid 
(0.4M) and chromic acid (0.2M) 
2. Micropattern AAO process 
 Device fabrication involves two aspects: fabrication of anodic aluminum oxide 
(AAO) nanopore thin film-based sensors and a PDMS microfluidic layer, and fabrication 
process flow for the micropattern AAO nanopore thin film sensor is shown in Fig. 3.1. 
Combining the anodization process of Al thin film with optical lithography, the fabrication 
process of the microfluidic interface is shown in Fig. 3.3.  
The detailed fabrication process of the micropatterned anodic aluminum oxide sensor 
is shown in Fig.3.1. A 3″ ⅹ 1″ glass substrate is first washed thoroughly in four steps: DI 
water, acetone, IPA and more DI water in sequence. An approximately 10 nm thick titanium 
layer and a 2 μm thick aluminum layer are then deposited on the glass substrate by E-beam 
evaporation as shown in Fig 3.1(b). The purpose of the titanium layer is to enhance adhesion 
between aluminum and glass. The anodization process (either one-step or two-step) uses 0.3 
M of chromic acid (H2CrO4) solution at 30V applied voltage at 5 °C for approximately 60 
mins (one-step process), forming an approximate 1.2 μm to 1.4 μm thick AAO layer on the 
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glass substrate. Besides, for the two-step anodization process of forming AAO, the Al-coated 
glass substrate is placed into a chromic solution for about 20 minutes under the same 
conditions as in the one-step process, the sample is etched using 6wt.% phosphoric acid 
(H3PO4) at room temperature for 10 minutes, then, put back into the chromic solution for 
anodization process for another 40 minutes, forming an AAO thin film on the glass substrate. 
In this study, we used a one-step anodization process to form our AAO nanopore thin film. 
To integrate the AAO sensor with the microfluidics device, we required a size 
reduction process, called Micropattern AAO. E-beam evaporation was first used to deposit a 
thin layer of aluminum on the AAO surface, followed by a spun a layer of photoresist AZ on 
which a photomask pattern of Fig 3.2, was created to selectively protect areas to be exposed 
to UV light. After UV exposure the glass substrate was immersed in AZ developer to remove 
exposed photoresist, as shown in Fig 3.1(f). Once photoresist windows have been open, the 
unprotected Al was etched with aluminum etchant. Once the exposed Al was completely 
etched away, the glass substrate was immersed into AAO etchant to remove the unprotected 
AAO layer, as shown in Fig 3.1(g). Finally, the photoresist layer was developed, and Al layer 
etched in sequence. revealing the AAO nanopore thin film sensor on the glass substrate 
indicated in Fig 3.1 (h).  
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Fig 3. 1 Fabrication flow of micropattern AAO thin film sensor 
 
 
Fig 3. 2 Photomask of micropattern AAO nanopore thin film with the diameter of 3.5 mm 
 
3. Microfluidic Device Fabrication Process 
To fabricate the microfluidics interface for the optical sensor, a mold was designed 




Fig 3. 3 SketchUp designed photomask for optical sensor. 
 
This design consists of three rows of three sensors, each with a nanopore thin film 
layer. The sensors were located at the center of the white circular area of diameter 4 mm, and 
each sensor has a diameter of about 3.5 mm. The microfluidic channel has two different 
dimensions, as shown in Fig 3.3, with a 400 μm wide thick channel and 250 μm wide thin 
channel.  
 Photolithography was used to create mold using the fabrication process illustrated in 
Fig. 3.4. A 3″ silicon wafer was first cleaned with acetone and DI water, followed by pouring 
a pile of SU-8 on the wafer until it covered most of the wafer surface. The wafer was then 
spun on a spin coater at 2000 rpm for 30s, producing a 100 μm thickness, then soft-baked 
overnight at 45 °C. The designed photomask was then placed on the SU-8 coated wafer, 
followed by an UV exposure dose of 220 mJ/cm2. Next, a hotplate set at 90°C provided a 
post-exposure bake directly after exposure, and once a clear view of the pattern emerged, the 
wafer was immersed in SU-8 developer to remove unexposed photoresist, while checking the 
pattern every 30s until only the microfluidics channel remained on the wafer. As a final step, 




Fig 3. 4 Cross-section view of photolithographt and PDMS soft lithography process  
 
Once the mold where the fluidic is to eventually flow has been formed on the wafer, 
as shown in Fig 3.4(c), a PDMS mixture of silicone elastomer base and curing agent in a ratio 
of 1:9 was poured on the mold, followed by 2 hours of degassing and 2 hours of curing at 
75°C. PDMS was then peeled off and the mold pattern transferred to the PDMS replica, then 
plasma bonded with the gold-coated patterned AAO sensor, as shown in Fig 3.4(f).  
 
3.3 Results and Discussion  
1. Fabricated Device 
The 3D sketch of the device is illustrated in Fig 3.5. Using the fabrication flow in Fig 
3.1 and Fig 3.4, the microfluidic devices have been fabricated. A photo of a fabricated device 
is illustrated in Fig 3.6. It has 9 sensors in three rows and each row has 3 identical sensors. 
The 3 sensors in each row are used to detect the same antibody. The measurement for one 




Fig 3. 5 Schematic of a device containing 3-row nanopore thin-film based sensors 
 
 
Fig 3. 6 (a) photo of a fabricated device containing 3-row nanopore thin-film based sensors; 
(b) SEM image showing the nanopores of the sensor.  
 
2. Microfluidic Operation Demonstration  
Three food dyes representing three different autoantibodies were used to demonstrate 
the functionality of the microfluidic network as shown in Fig 3.7. The surface 
functionalization process, shown in Fig 2.2, was carried out by flowing chemicals through 
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inlets. Specifically, HSC10COOH/HSC8OH and NHS/EDC flowed in Inlet 1 and Inlet 2, 
followed by three antigens introduced through Inlet 3, Inlet 4 and Inlet 5, respectively, 
loading the EA into entire sensor either through Inlet1 or Inlet 2. After these steps, surface 
functionalization of all sensors on this device has been accomplished.  
Three autoantibodies could then be introduced through Inlet 3, Inlet 4 and Inlet 5. For 
the demonstration, three autoantibodies, mimicked by three food dyes (blue, red and green), 
could be simultaneously detected by the sensor on device.   
 
 
Fig 3. 7 Photo of the device: three food dyes (blue, red and green) to mimic three 
autoantibodies inside the chip showing its capability for multiplexed detection of three 
autoantibodies (insulin Ab, GAD Ab, and IA-2 Ab) by three sensors in three rows.  
 
 
3. Measurements and Data Analysis  
The measurements were carried out using a specifically designed optical fiber probe 
and a portable spectrometer (Ocean Optics, Inc.,) [5] the same optical equipment used in 
previous experiments. After autoantibodies were applied to the sensors and waiting 
approximately 30-50 for signals to become stable, and three-time rigorous rinse by PBS 
buffer were used to remove unbound autoantibodies on the sensor surface, after which, 
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results were obtained using three optical measurements. Furthermore, we also increased the 
concentrations of all three autoantibodies to be the same as those described in Chapter 2, then 
loaded them into sensors and obtained results by measuring their optical signals.  
The test results were consistent with those generated by tests that directly applied 
samples onto the AAO thin film-based sensor. The total fringe shift of insulin in serum and 
the total fringe shift of insulin in buffer were ~8.7 nm and, ~6.3 nm respectively, compared 
with previous results of insulin, ~8.2 nm, ~6 nm in serum and in buffer. There were about 7.8 
nm and 8.8 nm fringes shift for the GAD antibody and IA-2 antibody, while previous 
experiments had produced GAD Ab and IA-2 Ab signal shifts of ~8 nm and, ~9.2 nm, 
indicating a good consistency of results for both experiments. Overall, three autoantibodies 
against insulin, GAD, and IA-2 can be simultaneously detected by AAO thin film-based 
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CHAPTER 4.    CONCLUSION  
In this thesis, the label-free optical sensor multiplexed detection of autoantibodies for 
Type 1 Diabetes has been reported. Autoantibodies against insulin, glutamic acid 
decarboxylase (GAD), and insulinoma associated protein-2 (IA-2) have been well-established 
in T1D panels and detecting the levels of such antibodies in samples is of a great interest, 
resulting in many approaches have been proposed for this purpose. Herein, anodic aluminum 
oxide nanopore thin-film based sensor integrated with microfluidic interface has been 
introduced to detect the autoantibodies in both a sample buffer and in serum. The AAO 
nanopore can be regarded as having in its cavity a nanostructured Fabry-Perot interferometer, 
a reactive-index sensitive optical sensor. We surface-functionalized the sensor with antigens, 
then applied the corresponding antibodies, and the transducing signal of the Fabry-Perot 
interferometer varied with the change of the effective refractive index in its cavity once the 
antibodies had bonded with the antigens. Different concentration of antibodies would result 
in distinct refractive index changes to yield different optical signals, and by observing optical 
signals shift, we can detect whether or not the sample contains autoantibodies. The specificity 
of the sensors was also evaluated, and a good specificity was indicated. The AAO nanopore 
thin-film based sensor was also integrated with microfluidic system, and it exhibited 
capability for simultaneously detection of all three autoantibodies.  
By taking advantages of both anodic aluminum oxide thin film and microfluidics, we 
have made a contribution to detecting Type 1 Diabetes, and the demonstrated multiplexed 




APPENDIX A. ANODIC ALUMINUM OXIDE FORMATION MECHANISM  
Anodizing is an electrochemical process for converting metal surface into a corrosion 
resistant, anodic oxide finish. During the anodization process, the metal surface will grow an 
anodic oxide layer. For Aluminum, this process causes a porous oxide structure called anodic 
aluminum oxide (AAO) is formed on the Al surface.  
The fabrication of AAO can be performed in the laboratory using the equipment 
shown in Fig. A1. The entire anodization process takes place in a reaction container filled 
with acid solution, with an associated cooling system connected to the tank to keeps flowing 
the water with the temperature at 2°C to 8°C to maintain the reaction temperature. The acid 
solution such as chromic acid, oxalic acid, phosphoric acid, or sulfuric acid is used as the 
electrolyte. Two electrodes, aluminum (Al) as the anode and platinum (Pt) as the cathode, are 
connected to a DC power supply that applies DC voltage between the two electrodes, causing 
the aluminum to gradually convert into anodic aluminum oxide. During this process, a 
stirring bar and magnetic stirrer are employed to maintain concentration uniformity in the 
acid solution.  
Generally, the anodic aluminum oxide formation can be described using the equation 
𝐴𝑙 + 𝑎𝑐𝑖𝑑 + 𝑣𝑜𝑙𝑡𝑎𝑔𝑒 → 𝑛𝑎𝑛𝑜𝑝𝑜𝑟𝑒𝑠 . The nanopore size is determined by the type of acid 
solution and amount of applied voltage. AAO formation is accomplished in two stages. In the 
first stage, a constant current density is maintained, while the voltage increases, and to 
maintain the current density, a barrier layer grows to maintain constant electric field strength. 
In the second stage, the barrier layer grows by a combination of migration of Al3+ ions 
outwards into the electrolyte and inward motion of O2- and OH- ions. The O2- and OH- ions 
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combine with Al to form oxide as shown in Fig. A2(a). During the oxide formation process, 
the barrier is constantly regenerated with further oxide growth, transforming into a semi-
spherical oxide layer of constant thickness that forms the pore bottom, as shown in Fig. 
A2(b). The overall reaction can be summarized by the following equations. 
 
Porous oxide layer formation process, Al dissolve in electrolyte  
2𝐴𝑙 → 2𝐴𝑙3+ + 6𝑒− 
Chemical reaction at the cathode which produces hydrogen gas 
6𝐻+ + 6𝑒− → 3𝐻2 
Oxygen anions react with Al at metal/oxide boundary 
2𝐴𝑙 + 3𝑂2− → 𝐴𝑙2𝑂3 + 6𝑒
− 
Al cations react with water molecules at oxide/electrolyte boundary 
2𝐴𝑙3+ + 3𝐻2𝑂 → 𝐴𝑙2𝑂3 + 6𝐻
+ 
Overall reaction at electrode  
2𝐴𝑙 + 3𝐻2𝑂 → 𝐴𝑙2𝑂3 + 3𝐻2 
 





Fig A. 2 (a) Schematic of the major features involved in the formation of the barrier layer. (b) 
Schematic of pore formation mechanism in an acidic electrolyte [1]   
 
Appendix A is summarized of journal paper, Progress in nano-engineered anodic aluminum 
oxide membrane development. 
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APPENDIX B. SURFACE FUNCTIONALIZATION MATERIALS AND PROTOCOL  
Material  
HSC10COOH/HSC8OH (To form chemical bond on gold surface) 
◆ 0.1mM 11-Mecaptoundecanoic acid (HSC10COOH) and 0.9 Mm 8-Mercapto-1-Octanol 
(HSC8OH)  
NHS/EDC (activating reagent) 
◆ 0.2 M N-hydroxy succinimide (NHS) and 005 M N-(3-dimethylamnopropyl)-N-ethyl 
carbodiimide hydrochloride (EDC) in DI H2O 
1 M ethanolamine (EA) dissolved in DI H2O (To occupy the non-bonding spot) 
Autoantibodies against insulin, GAD, and IA-2 dissolved in buffer and serum 
◆ Insulin antibody is from Human Anti-Insulin IgG ELISA Kit, purchased from Alpha 
Diagnostic International Inc.  
Measuring the insulin antibody and dilute in both buffer and serum to yield the 
antibodies at concentration of 0.1 U/ml, 0.4 U/ml, 1.6 U/ml, 6.3 U/ml, 12.5 U/ml, 50 
U/ml 
◆ Glutamic Acid Decarboxylase antibody is purchased from vendor (Kronus. Inc.)  
Dilute the GAD Antibody into serum to get concentration at 0.1 U/ml, 0.5 U/ml, 1 U/ml, 
5 U/ml, 10 U/ml, and 50 U/ml. 
◆ Insulinoma associated Protein-2 is purchased from vendor (Kronus. Inc.). 
 Dilute IA-2 Antibody into serum to get concentration at 0.5 U/ml, 1 U/ml, 5 U/ml, 10 





In order to promote the surface functionalization process, a thin gold layer is sputtered 
on the anodic aluminum oxide surface to enhance the optical properties of the sensor. The 
transducing signals from the gold coated sensor is much apparent than the signal directly 
obtaining from the AAO thin film. The surface functionalization procedure is illustrated in 
Fig. 2.2. The step by step surface functionalization process is described below.  
i. Prepare the Au coated AAO slides, rinse it with deionized water, acetone, 
Isopropyl alcohol (IPA) and deionized water one by one for three times. Dry out 
the AAO slides. And record the initial fringes. 
ii. Using pipet to load enough HSC10COOH/HSC8OH solution to cover AAO 
surface and incubate it at 4 ℃ overnight.  
iii. Rinse the AAO slides thoroughly with ethanol and DI water for three times. Dry 
out and record the fringes.  
iv. Apply NHS/EDC solution to cover AAO slides at room temperature for 2 hours.  
v. Rinse the AAO slides with phosphate buffered saline (PBS) and DI water three 
times and dry out.  
vi. Apply the antigens onto the AAO surface at 4 ℃ overnight. 
Recommend antigens concentration:  
Insulin antigen: 0.1 mg/ml 
GAD antigen: 3 μmol/L  
IA-2 antigen: 3 μmol/L 
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vii. Rinse the AAO slides with PBS and DI water thoroughly for three times, dry out 
and record the fringes. 
viii. Apply EA solution onto AAO surface at room temperature for 2 hours.  
ix. Rinse the AAO slides with PBS and DI water for 3 times, dry out and record 
fringes.  
 
After above steps finished, the surface has been functionalized with the specific 








APPENDIX C.THE OPERATIONAL PRINCIPLE OF ANODIC ALUMINUM OXIDE 
The label-free optical sensor is anodic aluminum oxide thin film based which is a 
honeycomblike nanostructure. Inside the structures’ cavity, it’s a nanostructured Fabry-Perot 
interferometer (FPI) coated with a layer of gold. For the label-free biosensing, there are three 
main transducing mechanisms, which include electrical, mechanical and optical response. 
Electrical transduction is realized where the electrical conductance varies upon the binding 
between receptors and targets. Mechanical transduction is achieved by the binding between 
receptors and targets, resulting in its bending and resonant frequency shift due to the surface 
stress variance. In addition, FPI is a refractive-index sensitive sensor, the transducing signal 
will shift as the surface properties varying.[1]  
As mentioned in surface functionalization process, we functionalize the AAO thin 
film surface with the chemicals, antigens, and antibodies. These processes could change the 
nanostructured surface properties. Immobilization of antibody receptors on the nanostructure 
layer and its binding with antibodies inside FPI are monitored in real time, resulting in 
transducing signal shift.  
The Fig.C1 indicates the nanostructured FPI sensor. The AAO sensor is integrated 
with the microfluidic interface. FPI cavity is serving as the biosensing area, the gold layer is 
coated on the surface of the nanopore which is to amplified transducing signals. The optical 
fiber emits the light signals and gets the reflected signal from FPI. Specifically, after the 
receptor (Ag) is attached on the sidewall of the nanopores, we can get the reflected signal 
from the sensor called S1. After antibody binding with the receptor (Ag), we can get another 
reflected signal from the sensor, called S2. The difference between S1 and S2 is Δλ which is 
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the fringes shift occurred between two conditions since it’s a refractive-index sensitive 
optical sensor, the transducing signal of a Fabry-Perot interferometer varies on the changes of 
the effective.   
 
Fig C. 1 Schematic of the label-free nanostructured uFPI biosensor: Au-coated nanostructures 
are embedded in the FPI cavity [2][3] 
 
 
Fig C. 2 (a) Immoblization of antigen on the side wall of the nanopore, and after binding with 
antibody. (b) fringes indicate the signal produced from receptor only and after binding with 
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